Trending Up0.2100 (9.3750%)
  • Bid / Lots
    2.3900/ 1
  • Ask / Lots
    2.4800/ 4
  • Open / Previous Close
    2.3000 / 2.2400
  • Day Range
    Low 2.2400
    High 2.5712
  • 52 Week Range
    Low 2.0500
    High 16.5000
  • Volume
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 2.24
09:32 ET20502.2503
09:33 ET15252.2829
09:35 ET9392.245
09:37 ET4252.2421
09:44 ET2502.25
10:08 ET2002.26
10:11 ET1002.2691
10:20 ET8002.2799
10:22 ET90202.32
10:29 ET27602.3499
10:33 ET12002.3899
10:36 ET20502.37
10:38 ET6982.3301
10:40 ET3002.3899
10:42 ET20002.3659
10:45 ET8522.3813
10:49 ET1002.39
10:54 ET2002.37
10:58 ET21102.39
11:00 ET17562.4199
11:02 ET9142.42
11:03 ET2502.38
11:09 ET39942.4
11:14 ET2402.42
11:20 ET18252.43
11:32 ET16002.3821
11:34 ET4002.4
11:52 ET11252.4199
11:59 ET4702.39
12:01 ET1002.36
12:37 ET1002.395
12:39 ET1002.3701
12:42 ET1002.37
01:00 ET5002.3701
01:11 ET3002.3701
01:13 ET2002.3748
01:15 ET1002.37
01:27 ET8312.3925
01:29 ET131082.5336
01:31 ET39182.43
01:33 ET2502.54
01:42 ET67992.36
01:44 ET3002.43
01:49 ET1962.4838
01:56 ET2002.43
02:21 ET5002.3901
02:38 ET1162.425
02:57 ET10002.425
02:59 ET9962.3954
03:01 ET1002.39
03:08 ET30942.415
03:10 ET9332.43
03:12 ET21002.3856
03:15 ET1002.4074
03:26 ET5992.4399
03:33 ET2002.43
03:37 ET8382.42
03:53 ET1002.38
03:57 ET47632.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCNSP
CNS Pharmaceuticals Inc
United StatesPHBI
Pharmagreen Biotech Inc
United StatesMGGI
Magicstem Group Corp
United StatesXSNX
NovAccess Global Inc
United StatesCFRX
ContraFect Corp
United StatesPTEO
Proteo Inc
As of 2023-02-04

Company Information

CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and central nervous system (CNS) oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. Additionally, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.

Contact Information

2100 West Loop S Ste 900HOUSTON, TX, United States 77027-3522


Chief Executive Officer
John Climaco
Chief Financial Officer
Christopher Downs
Chief Science Officer
Donald Picker
Chief Medical Officer
Sandra Silberman
Lead Independent Director
Jeffry Keyes

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.